<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929666</url>
  </required_header>
  <id_info>
    <org_study_id>ZWI-ZW25-201</org_study_id>
    <nct_id>NCT03929666</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of ZW25 Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma</brief_title>
  <official_title>Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymeworks Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zymeworks Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate
      the safety, tolerability, and anti-tumor activity of ZW25 plus physician's choice of
      combination chemotherapy in HER2-expressing gastroesophageal adenocarcinoma (GEA). Eligible
      patients include those with unresectable, locally advanced, recurrent or metastatic
      HER2-expressing GEA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus physician's
      choice of first-line combination chemotherapy (XP, FP, mFOLFOX6, or XELOX) and will confirm
      the recommended dosage (RD) of ZW25 when administered in combination with each of these
      multi-agent chemotherapy regimens. Then, Part 2 of the study will evaluate the anti-tumor
      activity of ZW25 plus physician's choice of combination chemotherapy in HER2-high GEA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) (Part 1)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Number of participants who experienced a DLT. DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Part 1)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lab abnormalities (Part 1)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Part 2)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of either complete or partial response during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) (Part 1)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of either complete or partial response during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Parts 1 and 2)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of complete response, partial response, or stable disease during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median duration of response (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median progression-free survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median overall survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who develop ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of infusion concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (Part 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of lab abnormalities (Part 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>HER2-expressing Gastroesophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>ZW25 + XP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus capecitabine and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus fluorouracil (5-FU), leucovorin, and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus 5-FU, leucovorin, and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus capecitabine and oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZW25</intervention_name>
    <description>Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)
Part 2: RD identified in Part 1</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_label>ZW25 + XP</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered orally twice daily (PO bid)</description>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_label>ZW25 + XP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + XP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Disease diagnosis:

               -  Part 1: Unresectable, locally advanced, recurrent or metastatic HER2-expressing
                  GEA (IHC 3+ or 2+ with or without gene amplification based upon local assessment
                  or central assessment)

               -  Part 2: Unresectable, locally advanced, recurrent or metastatic HER2-high GEA
                  (IHC 3+, or IHC 2+ and FISH+ by central review)

          -  Tumor measurements as per Response Evaluation Criteria in Solid Tumors (RECIST)
             version 1.1:

               -  Part 1: Measurable or non-measurable disease

               -  Part 2: Measurable disease

          -  ECOG performance status score of 0 or 1

          -  Adequate organ function

          -  Adequate cardiac left ventricular function, as defined by a LVEF &gt;/= institutional
             standard of normal

        Exclusion:

          -  Prior treatment with a HER2-targeted agent

          -  Treatment with prior anti-cancer therapy, except prior adjuvant/neoadjuvant therapy,
             which must be completed at least 6 months prior to first study treatment dosing;
             and/or treatment with other cancer therapy, not otherwise specified in the exclusion
             criteria, within 4 weeks before the first dose of ZW25

          -  Untreated known brain metastases (patients with treated brain metastases who are off
             steroids and are stable for at least 1 month at the time of screening are eligible)

          -  Having clinically significant cardiac disease or known myocardial infarction or
             unstable angina (within 6 months before first study treatment dosing)

          -  QTc Fridericia (QTcF) &gt; 450 ms

          -  Peripheral neuropathy &gt; Grade 1 per NCI-CTCAE v5.0

          -  Clinically significant interstitial lung disease

          -  Prior or concurrent malignancy whose natural history or treatment has the potential to
             interfere with the safety or efficacy assessment of the investigational regimen.

          -  Active hepatitis B or hepatitis C infection or other known chronic liver disease or
             infection with Human Immunodeficiency Virus (HIV)-1 or HIV-2 (Exception: patients with
             well controlled HIV [e.g., CD4&gt;350/mm3 and undetectable viral load] are eligible.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Josephson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zymeworks Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zymeworks Clinical Trial Resource</last_name>
    <phone>(206) 237-1030</phone>
    <email>medinfo@zymeworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Syma Iqbal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rutika Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Ku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Crystal Denlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaffer Ajani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel Goodwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Elimova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keun-Wook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young Mi Seol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yeul Hong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sun Young Rha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Biparatopic antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gastric cancers</keyword>
  <keyword>Esophageal cancers</keyword>
  <keyword>Gastroesophageal junction (GEJ) cancers</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>XP</keyword>
  <keyword>FP</keyword>
  <keyword>mFOLFOX6</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Leucovorin (folinic acid)</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>XELOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

